Peptech Articles
AVEO licenses Peptech's Superhumanisation technology
8 October 2007
Peptech's six-month profits soar to $133M
28 May 2007
Peptech to buy EvoGenix for $129M
14 May 2007
Peptech to deepen pipeline following Domantis sale
18 December 2006
Peptech to join AIM, as 2006 income falls 80.2%
4 December 2006
Peptech and Domantis enter antibody accord
8 August 2005
Domantis and Peptech find lead candidate
18 April 2005
Peptech and Agenix dump merger plans
14 June 2004
Domantis/Peptech's anti-TNF alpha antibody in RA
2 June 2003
Peptech's new chairman
29 April 2002
Diversys raises $20 million
5 April 2001
BASF loses IP challenge against Peptech
29 November 1999
Allergan Pulls Out Of Peptech Collaboration
22 October 1997
Peptech Appointments
18 September 1997
Appointments At Peptech
3 July 1997
Peptech And Medical Research Council Alliance
19 May 1997
Australia's Peptech To Seek London Listing
23 September 1996
Peptech's Psoriasis Drug
3 June 1996
Allergan Option On GMDP Products
7 August 1995
New Psoriasis Treatment
2 January 1995
Showing 1-24 of 24 articles
- 1
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
